an 019

AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.

CMF019 is a potent agonist of the Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ (pKis: 8.58, 8.49, and 8.71 for the human, rat, and mouse).

SJB3-019A is a potent, potent and novel ubiquitin-specific protease 1 (USP1) inhibitor, which promotes ID1 degradation and cytotoxicity in K562 cells 5 times more than SJB2-043, with IC50 of 0.0781 μM. SJB3-019A inhibits cell proliferation and causes cell apoptosis.

RGX-019 is a human-derived antibody expressed in CHO cells, targeting MER/MERTK. It features huIgG1 type heavy chains and huκ type light chains, with an estimated molecular weight (MW) of 150 kDa. The isotype control for RGX-019 can be found under HumanIgG1kappa, Isotype Control.

SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a DC50 of 0.3 μM[1].

KR019 is a potent hepatitis B virus (HBV) capsid assembly modulator that demonstrates significant antiviral activity in HBV cells. It binds to the hydrophobic pocket at the core protein dimer-dimer interface, redirecting capsid assembly into genome-free capsids, thereby inhibiting viral replication.

XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.